BioRestorative Therapies, Inc. (BRTX) Earnings History
Annual and quarterly earnings data from 2010 to 2024
Loading earnings history...
BRTX EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
BRTX Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 93.0% | -2881.6% | -2239.2% |
| 2023 | 100.0% | -10439.5% | -7145.2% |
| 2022 | 100.0% | -15838.1% | -11037.0% |
| 2021 | 100.0% | -57191.0% | -96311.5% |
| 2020 | 100.0% | -3574.1% | -14639.9% |
Download Data
Export BRTX earnings history in CSV or JSON format
Free sign-in required to download data
BioRestorative Therapies, Inc. (BRTX) Earnings Overview
As of May 8, 2026, BioRestorative Therapies, Inc. (BRTX) reported trailing twelve-month net income of -$13M, reflecting +53.0% year-over-year growth. The company earned $-1.39 per diluted share over the past four quarters, with a net profit margin of -2239.2%.
Looking at the long-term picture, BRTX's historical earnings data spans multiple years. The company achieved its highest annual net income of -$2M in fiscal 2010.
BioRestorative Therapies, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MESO (-$102M net income, -593.9% margin), XTNT ($2M net income, -14.0% margin), MDXG ($31M net income, 11.6% margin), BRTX has room to improve margins relative to the peer group. Compare BRTX vs MESO →
BRTX Earnings vs Peers
Earnings metrics vs comparable public companies
BRTX Historical Earnings Data (2010–2024)
15 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$9M | +13.8% | -$12M | $-1.16 | -2239.2% | -2881.6% |
| 2023 | -$10M | +21.2% | -$15M | $-2.47 | -7145.2% | -10439.5% |
| 2022 | -$13M | +70.2% | -$19M | $-3.65 | -11037.0% | -15838.1% |
| 2021 | -$44M | -293.0% | -$26M | $-37.30 | -96311.5% | -57191.0% |
| 2020 | -$11M | +23.0% | -$3M | $-28.56 | -14639.9% | -3574.1% |
| 2019 | -$15M | -17.0% | -$8M | $-3217.82 | -11267.6% | -6486.2% |
| 2018 | -$13M | -32.5% | -$8M | $-4269.37 | -11277.3% | -6889.8% |
| 2017 | -$9M | -9.4% | -$8M | $-6181.06 | -11660.1% | -10338.6% |
| 2016 | -$9M | -9.0% | -$8M | $-7356.30 | -23755.4% | -21447.6% |
| 2015 | -$8M | -41.8% | -$7M | $-9580.99 | -1259.9% | -1140.1% |
See BRTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BRTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BRTX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBRTX — Frequently Asked Questions
Quick answers to the most common questions about buying BRTX stock.
Is BRTX growing earnings?
BRTX EPS is $-1.39, with earnings growth accelerating to +53.0%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-13M.
What are BRTX's profit margins?
BioRestorative Therapies, Inc. net margin is -2239.2%, with operating margin at -2881.6%. Below-average margins reflect competitive or cost pressures.
How consistent are BRTX's earnings?
BRTX earnings data spans 2010-2024. The accelerating earnings trend is +53.0% YoY. Historical data enables comparison across business cycles.